浙江迪耳药业

Zhejiang Dier Pharmaceutical is a comprehensive pharmaceutical company specializing in the research, development, manufacturing, and commercialization of traditional Chinese and Western medicine preparations, as well as active pharmaceutical ingredients (APIs). Founded in 1962 as the Jinhua Second Pharmaceutical Factory, the company operates as a wholly-owned subsidiary of Sichuan Goldstone Asia Pharmaceutical (SZSE: 300434). Its diverse product portfolio spans multiple dosage forms, including tablets, hard capsules, oral solutions, syrups, and ointments, targeting therapeutic areas such as musculoskeletal disorders, infectious diseases, and nutritional deficiencies. Notable commercial products include diclofenac sodium sustained-release tablets, which passed China's generic drug consistency evaluation in 2025, and amantadine hydrochloride. The company maintains advanced GMP-certified manufacturing facilities and distributes its products across domestic and international markets.